AEON Biopharma Insider Buys 1.18M Shares After Promising Early‑Stage Neurotoxin Data
Insider buying of AEON Biopharma’s stock signals confidence in its promising neurotoxin pipeline and early‑stage safety data, offering insight for investors and clinicians.
4 minutes to read
